Synchron Raises $200 Million to Advance Brain-Computer Interface Launch
Synchron has secured $200 million to speed up pivotal trials and prepare for the commercial release of its Stentrode brain-computer interface (BCI) system. BCI companies are innovating devices that decode brain signals to enable actions like hands-free control of digital gadgets.
Different Approaches in BCI Devices
The BCI devices under development vary significantly in their implantation methods and capabilities. Elon Musk’s Neuralink involves implanting a device by removing part of the skull, while Synchron’s Stentrode is inserted through a less invasive catheter procedure.
Each device balances invasiveness with signal quality. Synchron’s first-generation Stentrode has 16 electrodes, fewer than Neuralink’s N1 Implant which has 1,024 electrodes. Despite this, Stentrode still allows people with severe paralysis to operate personal devices effectively.
Future Plans and AI Integration
With the Series D funding, Synchron aims to leverage the strengths of its current device and address its limitations over time. The company plans to accelerate trials and commercial preparations for Stentrode while developing a next-generation, transcatheter high-channel whole-brain interface.
"Artificial intelligence is part of Synchron’s strategy. The company is growing an AI team in New York City that is training models to learn from brain data. Synchron’s goal is to decode thought in real time."
Summary
Synchron’s $200 million funding will accelerate trials and enhance brain-computer interface technology with a focus on less invasive methods and AI-powered thought decoding.